Entrectinib/Luo Shengquan combination regimen
Entrectinib is a targeted therapy drug, mainly used to treat non-small cell lung cancer (NSCLC) and other solid tumors with ALK, ROS1 and TRK gene rearrangements. During treatment, entrectinib is often used in combination with other treatments to enhance efficacy and expand the scope of indications. The choice of combination therapy depends on the patient's specific condition, tumor type, and the patient's tolerance of the drug.

Combination regimens of entrectinib usually include combinations with other targeted drugs, chemotherapy drugs or immunotherapy drugs. For example, in patients with ALK-positive or ROS1-positive non-small cell lung cancer, entrectinib can be combined with other targeted drugs (such as crizotinib), which can help overcome drug resistance problems and further improve efficacy. Some patients can also be combined with immune checkpoint inhibitors (such as PD-1 or PD-L1 inhibitors) on the basis of entrectinib treatment to enhance the anti-tumor response of the immune system.
In addition, combinations of entrectinib and chemotherapy drugs may also be considered in certain circumstances. Although targeted drugs are generally well-selected and tolerable, chemotherapy can have an intensifying effect in some patients with greater disease burden. Chemotherapy drugs such as platinum-based chemotherapy drugs (such as cisplatin, carboplatin) are often used in combination with entrectinib, especially when the tumor has become drug-resistant and other treatments have failed.
Clinically, the specific combination treatment plan should be formulated based on the individual characteristics of the patient. Doctors will make corresponding adjustments based on the treatment response, the specific type of tumor, and the patient's tolerance for side effects. When patients receive combination therapy, they need to undergo regular examinations to ensure the efficacy of the drugs and to deal with possible side effects in a timely manner.
Reference materials:https://www.roche.com/products/rozlytrek
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)